small molecule glp-1 receptor agonist In the ACHIEVE-1 phase 3 trial, the oral small-molecule orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with early type 2 diabetes A potent novel small molecule
Pay in 4 interest-free payments of $7.22 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13























